Company Description

HDAX Therapeutics is developing a targeted therapeutics platform for the safe and efficacious treatment of HDAC-driven pathologies such as brain cancers and neuropathies by rationally designing therapies to overcomes common drug challenges including weak binding, off-target toxicities, and poor pharmacokinetic profiles.